Decreased expression of BRCA1 may play a role in the etiology of sporadic breast cancer. Deletion and point mutant analysis of proximal promoter elements in the BRCA1 1a promoter revealed a 22 bp region which was critical for the expression of the promoter in MCF-7 cells, but had a much reduced eect in T47D cells. The main transcription factor interacting with this site was identi®ed as GABPa/b, and a discrete DNA binding complex was only observed in nuclear extracts from MCF-7 cells. Cotransfection experiments with GABPa and b1 expression vectors produced transactivation of this element in both lines. These results suggest that GABPa/b is a critical activator of BRCA1 expression, and that its activity may dier in human breast cell lines.
Introduction
Mutations in the BRCA1 and 2 genes have been identi®ed as being responsible for the majority of familial breast cancer cases (Casey, 1997) . However, no consistent pattern of mutation of these genes has been found in sporadic tumor samples (Futreal et al., 1994; Merajver et al., 1995; Miki et al., 1996; Teng et al., 1996; Lancaster et al., 1996) . In contrast, the expression of the BRCA1 gene has been reported to be decreased in a variety of sporadic breast tumors, and appears to be correlated with tumor progression (Thompson et al., 1995) . BRCA1 protein levels also decrease in higher grade tumors (Wilson et al., 1999) which may also involve a loss of nuclear BRCA1 staining (Jarvis et al., 1998) . Alterations in gene expression may result from preferential allelic expression of the BRCA1 gene (Ozcelik et al., 1998) or from loss of heterozygosity even in sporadic tumors . A series of papers has also suggested that methylation of the BRCA1 promoter may be a signi®cant factor in decreasing BRCA1 expression in sporadic breast tumors, possibly through inactivation of a CREB site (Mancini et al., 1998) . However, methylation can account for decreased BRCA1 expression only in a subset of sporadic breast cancer samples (Magdinier et al., 1998; Dobrovic and Simpfendorfer, 1997; Rice et al., 1998; Mancini et al., 1998; Catteau et al., 1999) . Overall, these results suggest that sporadic breast cancer may result from defects in the genes regulating the BRCA1 promoter, or that transformation leads to a concomitant down regulation of BRCA1 expression.
The expression pattern of BRCA1 in the mouse has suggested that this gene plays a role in proliferation and dierentiation of a wide variety of tissues, and particularly that of the breast (Lane et al., 1995; Marquis et al., 1995) . BRCA1 expression is also increased in proliferating cells (Gudas et al., 1996; Marks et al., 1997) . A general role for BRCA1 in development is supported by the early embryonic lethality of the homozygous BRCA1 knockout mouse (Liu et al., 1996; Hakem et al., 1996) . Conditional inactivation of the BRCA1 gene in the mouse breast resulted in both abnormal duct formation and tumors, con®rming a role for BRCA1 in both development and transformation of this tissue .
The BRCA1 gene has two alternative start sites, but it is the upstream 1a promoter which appears to be predominantly used in breast tissue . The BRCA1 gene forms a divergent transcription unit with the NBR2 gene (Brown et al., 1996; Xu et al., 1997a) , which lies immediately upstream, so that approximately 300 basepairs separate the transcriptional start sites for each gene. Initial characterization of the promoter revealed a potential negative regulatory region, as well as several proximal regions which are necessary for expression (Xu et al., 1997b) . Recently, a smaller, positive element which overlaps with one of the previously characterized positively acting regions has been de®ned (Thakur and Croce, 1999) .
We have carried out a functional analysis of the BRCA1 proximal promoter in two dierent human breast cell lines, T47D and MCF-7. Deletion analysis of the promoter reveals the presence of a conserved element approximately 230 bp upstream of the transcriptional start site which is critical for ecient transcription of the promoter, particularly in MCF-7 cells. The eect of this site in T47D cells was signi®cantly reduced in comparison to MCF-7 cells. This 22 bp region, referred to as the RIBS element, contains three potential ets protein binding sites. Point mutations of these sites, made individually and in combination, revealed that the central CGGAA ets site was of particular importance for promoter activity in MCF-7 cells, but it had a minimal eect in T47D cells. Analysis of nuclear extracts from both breast cell lines revealed that a speci®c complex was formed only with the MCF-7 extracts. This recognition site is most closely related to that of the GABPa/b ets protein. The identity of this protein complex was con®rmed by crosslinking and supershift assays, as well as binding to recombinant GABPa/b. An arti®cial promoter containing the multimerized RIBS element was transactivated by GABP a and b1 expression vectors in both cell lines. These results indicate that GABPa/b is a key regulator of the BRCA1 promoter.
Results
The RIBS element is important for Brca1 promoter activity in MCF-7 cells Our initial analysis of the BRCA1 proximal promoter in both the MCF-7 and T47D human breast cancer cell lines indicated that an EcoRI to SacI fragment of the promoter comprising sequences from nt +27 to nt 7204, had optimal transcriptional activity (Figure 1,  L6 ). The inclusion of upstream sequences reduced expression, which may be due to a negative upstream element or competition from the NBR2 promoter (Thakur and Croce, 1999; Xu et al., 1997b) . We constructed a series of 5' deletions from the EcoRI site and assayed them for their transcriptional activity (Thakur and Croce, 1999) in the two cell lines. In MCF-7 cells, the deletion of the ®rst 22 basepairs (L6dR) resulted in a dramatic reduction in activity to less than 10% of the L6 promoter (Figure 1, lower) . Subsequent deletions had little additional eect until the removal of sequences downstream of nt 7143. This indicates that an important regulatory element which is active in MCF-7 cells lies within this ®rst 22 basepair region, which will be referred to as the RIBS (EcoRI bandshift) element. In contrast, assaying this same series of deletion mutants in T47D cells revealed a minimal eect of the L6dR mutant on transcriptional activity, with at most a twofold decrease in expression. However, deletion of an additional 24 basepairs to nt 7158 did result in a large decrease in transcriptional activity (Figure 1, USCAAT) . This indicates that the RIBS element does not appear to be active in T47D cells, but that an adjacent element between nt 7182 and nt 7158 is active in these cells.
The L6dR deletion was created based on a high degree of sequence conservation between the human and the mouse promoter sequences (Figure 2a) . Optimal alignment of the two promoters reveals that 24 of 26 nucleotides were identical in this region. The human Figure 1 Deletion analysis of the BRCA1 1A proximal promoter in MCF-7 and T-47D cells. A series of 5' deletion mutants of the BRCA1 proximal promoter was created in the reporter plasmid pGL2-Basic and they are illustrated in the schematic diagram. The transcriptional activity of these constructs when transfected into MCF-7 or T-47D cells is indicated as a percentage of the activity of the L6 construct (nt 7204 to +27), which exhibited maximal activity. Experiments were carried out in completely independent triplicates with an internal control consisting of the pRL-CMV plasmid. The average and standard deviation for each of the transfections is indicated beside the name of the construct. The upper schematic indicates the relative locations of the NBR2 exon 1 and BRCA1 exon 1A (black boxes). An EcoRI site at nt 7204 is indicated in the upper schematic and the location of the RIBS element is shown by the block box on the lower part of the schematic. The end points of the various deletions are indicated by nucleotide number in relation to the mRNA start site sequence contains three potential ets protein binding elements, comprised of the core GGAA sequence on the non-coding strand. However, only the central element is conserved between species, as the mouse sequence has A residues instead of Gs in the two outer ets sites. In order to identify the speci®c sequences required for function of this element, a series of point mutations were created, targeting the GG sequences within each of the potential ets sites (Figure 2a) . Mutation of the 3' ets site had no eect on promoter activity in MCF-7 cells (Figure 2b , CCM). In contrast, any promoters containing a mutation of the central ets site, either alone or in combination with the other mutants, was reduced approximately threefold in relation to the L6 promoter (TTM, AATTM and AATTCCM). This reduction was not as severe as deletion of the entire region (L6dR), indicating that other factors may also interact with this site, or that the mutations did not completely eliminate the binding of the factor. The same series of point mutations were also assayed in T47D cells ( Figure 2c ). They had a minimal eect on promoter activity, producing values that were intermediate between the activity of the L6dR and L6 constructs. These results indicate that the central ets site is important for the transcriptional activity of the BRCA1 promoter in MCF-7 cells, but that this element does not appear to be active in T47D cells.
RIBS element activity is differentially regulated
In order to determine if there is a dierence in the activity of the RIBS element in the two dierent cell lines, constructs were created which contained an oligomeric repeat of the 22 bp RIBS element de®ned by the L6dR deletion. This element was repeated ®ve times and was cloned in both orientations, upstream of a reporter construct consisting of a TATA box derived from the albumin gene, a G-free cassette, and the ®re¯y luciferase gene (Figure 3 , lower). These constructs were transfected into MCF-7 and T-47D cell lines, and their activity was compared to both the SV40 early promoter and the L6 BRCA1 construct. When normalized against the SV40 promoter, the L6 promoter construct was 1.75-fold more active in MCF-7 cells as compared to T47D cells (Figure 3, upper) . The RIBS constructs were signi®cantly more active in MCF-7 cells when expressed either as a percentage of the pGL2-CTRL construct, or in relation to the BRCA1 L6 construct. When compared directly, the forward and backwards constructs were 3.4 and ®ve times more active in MCF-7 cells compared to T47-D cells. It would appear that the activity of the RIBS element is signi®cantly dierent between these lines and may result in greater promoter activity in MCF-7 cells.
Given cell line speci®c dierences in transcriptional activity of the RIBS site, we determined if there were dierences in the factors interacting with this site. Nuclear extracts prepared from the two cell lines were used in bandshift assays with a double stranded oligonucleotide corresponding to the region including all three potential ets binding sites (BRIBS). An intense faster migrating band was seen in both extracts, but only extracts from MCF-7 cells produced a more slowly migrating complex (Figure 4a , BRIBS). Self competition experiments indicated that the lower complex was nonspeci®c, but that the upper complex in MCF-7 cells was speci®c (Figure 4b , RIBS). An oligonucleotide incorporating mutations in the upstream and central ets sites abolished the binding of the slower migrating complex in the MCF-7 extracts ( Figure 4a , AATT mutant). These results suggested that the cellular factor does not interact with the AATT mutant. Competition experiments were carried out using the wild type RIBS probe with MCF-7 nuclear extracts and increasing concentrations of the unlabeled wild type or AATT mutant oligonucleotide. At a 10-fold molar excess the AATT mutant had a minimal eect on binding, while the wild type oligonucleotide competed eectively ( Figure 4b , RIBS verses AATT). These results indicate that the factor binding to the RIBS element is dierentially regulated in these cell lines and mutations that result in decreased promoter activity do not bind the factor present in MCF-7 cells.
The RIBS binding protein is GABPa/b
The central ets site is the only one conserved between the human and mouse promoters, and the analysis of point mutations in MCF-7 indicates that this site is essential for promoter activity. This ets site is most closely related to the recognition element for GABPa/ b, with the complementary strand sequence CGGAA-GAG, being identical to a GABPa/b element identi®ed in the COX4 gene (Virbasius et al., 1993) . GABPa/b consists of a tetramer made up of two a DNA binding subunits, and two b subunits, with the b1-1 and b1-2 forms derived from dierential splicing of one gene and the b2-1 form derived from a separate gene (de la Brousse et al., 1994) . The human forms of these proteins are known as hGABPa, while hGABPb1 is equivalent to the mouse GABP b1-1, and hGABPg1 is Figure 3 Activity of RIBS multimer constructs in MCF-7 and T-47D cell lines. Five copies of the 22 bp RIBS element were cloned in both orientations upstream of an arti®cial promoter consisting of the albumin TATA box and the luciferase reporter gene (schematic at bottom). The activity of these constructs and the L6 promoter construct, were compared to that of the pGL2-CTRL plasmid carrying the SV40 early promoter/enhancer elements. The results are expressed as a percentage of the activity of the pGL2-CTRL plasmid in each separate cell line. Experiments were carried out in completely independent triplicates with an internal control consisting of the pRL-CMV plasmid. The average and standard deviation of each of the experiments is indicated Oncogene GABPa/b regulates BRCA1 expression E Atlas et al equivalent to mouse GABPb1-2 (Sawa et al., 1996) . To date, a human form of GABPb2 has not been characterized. Recombinant forms of the mouse GABP a, b1-1 and b2 proteins were created as maltose binding protein fusions and used in bandshift assays with the BRIBS element. The a subunit alone was able to form a complex with this site, and the addition of either the b1 or b2 subunits resulted in a slower migrating complex (Figure 4a ). The AATT mutant oligonucleotide was unable to bind to any of the recombinant GABP complexes.
GABPa/b is thought to bind to a tandem repeated recognition element, consistent with the tetramer containing two DNA binding subunits. To determine if this is the case with the RIBS element we tested the eect of the individual AA and TT mutations, which mutated the upstream or central ets sites, on recombinant GABPa/b binding. With the a subunit alone, binding to the TT mutant was eliminated while binding to the AA mutant was dramatically reduced but not eliminated. In the presence of the b1 or b2 subunits some binding to the TT mutant was observed, but both the AA and TT mutants were dramatically reduced compared to the wild type oligonucleotide (Figure 4c ). These results indicate that GABPa/b binding to the RIBS element involves both ets elements, and that in the absence of tetramerization (mediated by the b subunits), mutation of the central ets site has the greater eect on binding.
In order to con®rm the binding of GABPa/b to the BRIBS element in MCF-7 extracts monoclonal antibodies directed against the human GABPa or b subunits were used to carry out supershift assays. The upper complex formed with MCF-7 extracts was shifted into a distinct slower migrating complex when the antibody to the a subunit was added (Figure 5a ). Some supershift was also seen with the anti-hGABP b1 (mouse b1-1) monoclonal antibody but a much greater shift was seen with the anti-hGABPg (mouse b1-2) antibody, which resulted in a complex which remained in the well. This indicates that in MCF-7 cells the GABPa/b complex does interact with the RIBS element and that the protein complex consists mainly of GABPa and g (mouse b1-2). Nuclear extracts were also prepared from breast tissue of lactating rats and used in bandshift and supershift assays but in this case using polyclonal antibodies directed against the mouse protein. A complex similar to that seen with the MCF-7 extracts was observed to form with the breast nuclear extracts (Figure 5b ). The addition of antibodies raised against mouse GABPa and b1 (recognising b1-1 and 1-2) resulted in the complete shift of the speci®c complex to a higher form which migrated at or near the well of the bandshift gel (SS). The b2 antibody produced only a partial shift in the speci®c complex, but did produce a distinct slower migrating complex. The antibody to the a subunit also appears to have shifted a more slowly migrating complex in these breast extracts, which may correspond to GABPa which is not complexed with the b subunits, as it is not shifted by antibodies to those proteins. These results indicate that in rat breast nuclear extracts the complex formed with the BRIBS element consists primarily of mGABPa and mGABPb1 proteins, but also includes a small amount of mGABPb2 protein. This is consistent with the results in MCF-7 extracts where the g subunit is the main factor present, which is equivalent to the mouse b1-2 subunit. In the mouse we can not distinguish the b1-1 and 1-2 subunits, while we can not detect the b2 subunit in human extracts. Further characterization of the proteins present in the cell lines involved DNA/protein crosslinking experiments using the BRIBS probe. Nuclear extracts from the T-47D and MCF-7 lines produced a complex of approximately 60 kilodaltons only with the MCF-7 extract (Figure 5c ). This is consistent with the 60 kilodalton molecular weight of the human GABPa protein, which is the main subunit contacting DNA. The nuclear extracts were normalized by both weight of protein and using the binding of the ubiquitous NF-Y factor as an internal control. A low level of a variety of bands common to both cell lines were also observed. These likely correspond to non-speci®c proteins or to a low level of other ets proteins which can bind to the probe due to the presence of the ets core sequence (GGAA) in the probe. Finally, Western blot analysis of the MCF-7 and T-47D extracts using several dierent antibodies indicate that comparable levels of all of the subunits are present in these cells (Figure 5c, WESTERN) . These results indicate that GABPa/b is likely the protein which Figure 4 (a) Analysis of RIBS element binding proteins. A 32 basepair probe (BRIBS) corresponding to the region from nt7204 to nt7176, encompassing the RIBS element, was used in bandshift assays with nuclear extracts derived from T-47D or MCF-7 cells. Bandshift assays with recombinant GABPa, GABPa and b1, or GABPa and b2 were also carried out with this probe. Identical assays with a probe incorporating the AATT mutation in the context of the RIBS element were also carried out. Only the DNA/protein complexes are shown in this ®gure. (b) Competition with wild type and mutant oligonucleotides. A bandshift assay was carried out with 1 ng of the RIBS probe and nuclear extracts from MCF-7 cells. Increasing amounts of the unlabeled RIBS or the AATT mutant oligonucleotide were added as indicated. The location of the speci®c DNA/protein complexes are indicated by the bracket marked B. (c) Binding of recombinant GABPa/b to wild type and mutant oligonucleotides. GABPa alone, or with the b1 or b2 subunits, was used in bandshift reactions with the wild type RIBS (W), the AA mutant (A), the TT mutant (T) or the double AATT mutant (AT). The location of the speci®c DNA/ protein complexes are indicated by the bracket marked B interacts with the RIBS element, and while the protein is present in both cells it appears to bind to the RIBS element only in MCF-7 nuclear extracts.
GABPa/b transactivates the RIBS site
In order to determine if the cotransfection of expression vectors for the GABP subunits could activate the RIBS element, mammalian expression vectors for mouse GABPa and b1 were created. When transfected into MCF-7 cells with the RIBS negative orientation multimer construct, a 4.6-fold increase in activity was observed ( Figure 6 , MCF-7,RIBS-). Transfection of T-47D cells with the GABP expression vectors resulted in a threefold transactivation of the RIBS multimer ( Figure  6 , T-47D,RIBS-). These results indicate that GABP can transactivate the multimer in both MCF-7 and T-47D cells, though the overall level of activity produced in MCF-7 cells is greater than in T47D cells. Comparable results were obtained when a mouse b2 expression vector was used and when expression vectors for human a, b1 and b2 were employed (data not shown). Attempts to transactivate the promoter with GABP in both cell lines, did not result in any signi®cant increase in activity (Figure 6, L6) . The reason for this lack of activation is not known, but has been observed with other ets protein binding sites when assayed in the context of the promoter.
Discussion
A growing number of studies have linked the decreased expression of the BRCA1 gene to both the initiation and progression of sporadic breast cancer (Thompson et Jarvis et al., 1998; Ozcelik et al., 1998; Catteau et al., 1999) . Characterizing the elements regulating the BRCA1 promoter is a crucial part of understanding how this change in expression occurs at the molecular level. Our initial analysis of the promoter identi®ed a 22 basepair region located Figure 5 (a) Supershift assay with MCF-7 nuclear extracts. The BRIBS probe was used in a bandshift assay with nuclear extracts from MCF-7 cells. Monoclonal antibodies directed against the human GABPa, b1 and g subunits were added to the binding reaction as indicated, or cell culture media was added as a control (7). The supershift complex is indicated (SS), as is the location of the DNA/ protein complex (B) and the free DNA (F). (b) Supershift assays with rat breast nuclear extracts. Nuclear extracts were prepared from the mammary glands of lactating rats 1 day after the pups were prematurely weaned. The nuclear proteins were used in supershift assays with the BRIBS probe with pre-immune serum (7), or with the addition of antibodies to GABPa, GABPb1 or GABPb2, as indicated. The supershift complex is indicated (SS), as is the location of the DNA/protein complex (B) and the free DNA (F). (c) Crosslinking and Western analysis of MCF-7 and T-47D nuclear extracts. The radiolabeled BRIBS probe was UV crosslinked in solution with nuclear extracts from MCF-7 or T-47D cells. The complexes were then separated on a SDS ± PAGE gel and autoradiographed (CROSSLINKING). The location of protein size markers, and their molecular weight in kilodaltons, is indicated on the side. Western blot analysis of these same extracts (WESTERN) was carried out using polyclonal antibodies raised against the mouse GABPa (mGABPa) or GABPb2 (mGABPb2) proteins, or using a monoclonal antibody to human GABPg (hGABPg) Figure 6 Transactivation of the L6 promoter and RIBS multimer constructs by GABP expression vectors. The L6 promoter (L6) and the RIBS negative orientation multimer construct (RIBS7) were transfected with the empty mammalian expression vector (7) or with expression vectors for GABPa and b1 (GABP). These transfections were carried out in both MCF-7 and T-47D cells as indicated. Experiments were carried out in completely independent triplicates with an internal control consisting of the CMV-pRL plasmid. The average and standard deviation of each of the experiments is indicated approximately 200 basepairs upstream of the transcriptional start site as being a strong positive element in MCF-7 cells. The location of this element is in keeping with previous analyses which identi®ed this same region as being important for BRCA1 promoter activity (Xu et al., 1997b; Thakur and Croce, 1999) . Fine analysis of this region identi®ed a central ets binding domain as the key transcription element within this region. Of the three GGAA core ets binding elements present in this region, only the central site is conserved between mouse and human. This would suggest that these¯anking sites are less important for promoter activity, given their lack of conservation. However, it is possible that there are species speci®c dierences in regulation of the BRCA1 promoter. Unlike humans, mice which are heterozygous for BRCA1 inactivation do not develop breast cancer. This could re¯ect species dierences in breast biology, some dierence in BRCA1 function or species speci®c developmental regulation of BRCA1 expression.
The sequence CGGAAGAG in the RIBS element is identical to a previously characterized GABPa/b site in the COX4 gene (Virbasius et al., 1993) , and is also a good match to other previously identi®ed GABPa/b elements. GABPa/b is thought to bind as a heterotetramer consisting of two molecules of the DNA binding a subunit, and two molecules of either the b1 or b2 subunits, which are encoded by separate genes (de la Brousse et al., 1994) . The tetramer is thought to bind preferentially to a tandem repeat of the recognition element, but several examples of GABPa/b binding to single elements have also been reported (Boccia et al., 1996; Nuchprayoon et al., 1997) . Experiments with recombinant GABPa/b and the point mutants in the RIBS element indicate that the upstream, as well as the central ets site, may be involved in binding (Figure 4c ). This suggests that the RIBS element is a tandem GABPa/b recognition element, but that the central ets site is the more important of the two. This tandem interaction would explain why the AAM mutant appears to have some eect on expression.
Supershift assays with MCF-7 and rat breast nuclear extracts suggest that most if not all of the binding activity in these extracts is GABPa/b. A number of other ets proteins have been described in human and mouse breast, but if they recognize this site, they comprise only a small proportion of the binding activity observed. These may produce the background bands observed in the crosslinking experiment ( Figure  5c ). The size of the DNA/protein complex observed in MCF-7 cells is consistent with that of the a subunit of GABP. The molecular weight of the ets factor PEA3 is close to that of GABPa. However, supershift experiments with PEA3 antibodies have not detected any complexes with the RIBS site in cell or tissue extracts (data not shown) and MCF-7 cells do not express PEA3 (Baert et al., 1997) .
The ability of GABPa/b to transactivate the RIBS oligomer but not the proximal promoter, may be due to transactivation of the proximal promoter requiring the cotransfection of other proteins which bind to sites adjacent to the GABPa/b site. This has been observed in the oxytocin receptor gene, where GABPa/b alone produced minimal promoter activation, but when cotransfected with fos and jun expression vectors, produced substantial transactivation (Hoare et al., 1999) . GABPa/b is ubiquitously expressed and its binding element has been found in a wide variety of promoters. It is of particular interest that GABPa/b has recently been linked to the regulation of several genes by the neuregulins, a group of proteins which interact with members of the ErbB receptor family. The up-regulation of both the acetycholine receptor (Fromm and Burden, 1998) and the utrophin (Khurana et al., 1999) genes in response to neuregulin treatment of nerve or muscle cells, requires GABPa/b sites located in the proximal promoters of these genes. Ampli®cation of the her2/ neu (ErbB2) receptor in sporadic breast cancer has been widely correlated with increased risk. The neuregulins are thought to signal primarily through the ErbB3 and ErbB4 receptors, though heterodimerization between ErbB2 and ErbB3 may be important for signalling (Tzahar and Yarden, 1998) . If GABPa/b is a downstream regulator of neuregulin signalling, then it is possible that disruption of signalling through her2/neu in breast cancer may alter the expression of the BRCA1 gene in these cells. GABPa/b has also been implicated in the regulation of the her2/neu gene itself (Scott et al., 1994) , suggesting some commonality in their regulation.
Methylation of the BRCA1 promoter has been suggested to play a role in the down regulation of BRCA1 expression in a subset of sporadic breast cancers. Frequent methylation of a putative CREB site which is immediately downstream of the RIBS element has been observed (Mancini et al., 1998) . We observed a 3.5-fold decrease in activity upon deletion of the region from nt 7182 to nt 7158 in T-47D that likely results from elimination of this CREB site. Mutation of this site also results in reduced promoter activity in both cell lines (EA, MS, CRM unpublished observation). Loss of the CREB site function due to methylation may also aect GABPa/b activity, particularly as there is only a single GABPa/b site present. GABPa/b binding may also be a direct target of promoter methylation, as a CpG site is present in the recognition element, and GABPa/b binding is known to be sensitive to methylation (Yokomori et al., 1998 ).
There appears to be fundamental dierences in the transcriptional regulation of the BRCA1 promoter between the MCF-7 and T-47D cell lines. This is re¯ected in the lack of GABPa/b activity and binding in T-47D cells. Western blot experiments indicate that both MCF-7 and T-47D cells express GABPa/b proteins suggesting that it is GABPa/b binding activity, rather than expression which is defective. MCF-7 cells are known to express levels of BRCA1 mRNA comparable to T-47D cells, despite one of the two BRCA1 loci being deleted in MCF-7 cells. This suggests that the endogenous BRCA1 gene is signi®cantly more active in MCF-7 cells compared to T-47D cells, possibly due to the observed dierence in GABPa/b activity in these lines. It is interesting to note that the up-regulation of BRCA1 mRNA in response to prolactin treatment of these two cell lines also diers, with a 12-fold increase in MCF-7 cells versus a twofold increase in T-47D cells (Favy et al., 1999) . Both lines are known to be positive for the estrogen receptor, and T-47D cells also express the progesterone receptor. Whether the dierence in GABPa/b activity in these lines is due to an intrinsic defect or a dierence in their response to growth conditions is currently being investigated. Disruption of GABPa/b activity, or loss of upstream signals modulating GABPa/ b activity, may represent a mechanism by which BRCA1 expression could be down regulated in sporadic breast cancer.
Materials and methods

Cell culture and transfection
The breast ductal carcinoma T-47D, and the breast carcinoma MCF-7 were obtained from the American type culture collection (Rockville, MD, USA). Cells were maintained in RPMI-1640 supplemented with 10% fetal calf serum and penicillin/streptomycin (Gibco ± BRL), and cultured in a humid atmosphere at 378C and 5% CO 2 . For transient transfections, cells were plated in triplicate in 12 well plates at 1610 5 cells/well 24 h prior to the transfection. A total of 0.8 mg of plasmid DNA, containing the indicated amounts of reporter plasmids and expression vectors, along with pRL-TK or pRL-CMV (Promega) for normalization of transfection eciency, was transfected using FuGENE (Boehringer-Mannheim) according to manufacturer's instructions. pSCT-Gal, the expression vector was previously described and was used to make up for the amount of DNA where appropriate. The cells were incubated with the DNA for 24 h, prior to replacement of the medium with fresh culture medium. Forty-eight hours post-transfection the cells were washed in phosphate buered saline, lysed in 150 ml passive lysis buer and 20 ml of the cell lysates were assayed using the dual luciferase kit according to the manufacturer's recommendations (Promega).
Nuclear extracts
Nuclear extracts were prepared from MCF-7 or T-47D cells as previously described (Armstrong et al., 1997) . Brie¯y, cells were cultured to near con¯uence in 100 mm plates, washed three times with phosphate buered saline, scraped and pelleted. The washed cells from 10 plates were lysed in 10 mls cell lysis buer (10 mM HEPES pH 7.6, 15 mM KCl, 2 mM EDTA, 0.5 mM spermidine, 0.15 mM spermine, 0.5% NP-40, 1% skim milk w/v, 10 mg/ml Aprotinin, 1 mM DTT, 0.1 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml pepstatin A) for 5 min at 48C, prior to overlaying on a 30% sucrose cushion in the same buer. Nuclei were pelleted by centrifugation at 1000 g, and resuspended in nuclear lysis buer (10 mM HEPES, pH 7.6, 100 mM KCl, 0.1 mM EDTA, 10% Glycerol, 3 mM MgCl 2 , 1 mM DTT, 0.1 mM PMSF, 10 mg/ml Aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM benzamidine) and lysed in 0.55 M KCl. Nuclear proteins were concentrated by (NH 3 ) 2 SO 4 precipitation to a concentration of 3 ± 5 mg/ml. Rat breast tissue was obtained from post-lactating mothers 1 day after the pups had been removed. Nuclear extracts were prepared from the tissue as described previously for rat liver (Boccia et al., 1996) .
Gel mobility assays
Gel mobility assays were performed in 20 ml binding reactions in 16binding buer (0.05 mg/ml poly (dl-dC) (Sigma), 0.5 mg/ml BSA (Sigma), 30 mM HEPES pH 7.6, 3 mM dithiothreitol, 3 mM EDTA, 150 mM KCl, 1% Ficoll) and incubated for 15 min on ice before separation on a 6% acrylamide 0.256TBE non-denaturing gel. For the supershift assays, the binding reactions were allowed to proceed as described, followed by incubation for 30 min on ice, with 1 ml of rabbit anti-GABP (a, b 1, or b 2 ) immune serum, (gifts from SL McKnight), or pre-immune serum as control. Supershift assays with monoclonal antibodies to the human GABP subunits were carried out in a similar manner using cell culture media containing sera as a negative control. These antibodies (anti-hGABP a, b1-1, or g (b1-2)) were a gift from H Handa. The BRIBS probe had the sequence: 5'-GAATTCTTCCTCTTCCGTCTCTTTCCTT-3' 3'-CTTAA-GAAGGAGAAGGCAGAGAAAGGAATTAA-5' while the RIBS and mutant probes had the following sequences: RIBS: 5'-AATTCTTCCTCTTCCGTCTCTTTC-3; 3-GAAGGAG-AAGGCAGAGAAAGTTAA-5'. TT mutant: 5'-AATTCTT-CCTCTTTTGTCTCTTTC-3 3-GAAGGAGAAAACAGA-GAAAGTTAA-5'. AA mutant: 5'-AATTCTTAATCTTCC-GTCTCTTTC-3; GAATTAGAAGGCAGAGAAAGTTAA-5'. AATT mutant: 5'-AATTCTTAATCTTTTGTCTCTTTC-3'; 3'-GAATTAGAAAACAGAGAAAGTTAA-5'.
Cross-linking
Cross-linking was performed as follows. Brie¯y, 5 mg protein of nuclear extracts were incubated as previously described for gel mobility assays with the 32 P-labeled BRIBS oligonucleotide and then exposed to UV light for 30 min in a UV Stratalinker 1800 (Stratagene). Samples were denatured by boiling in SDS sample buer followed by electrophoresis on a 12% SDS polyacrylamide gel. The gel was then ®xed, dried and autoradiographed.
Western blotting
Ten mg protein from nuclear extracts obtained from MCF-7 or T-47D cells were resolved on 10% SDS-polyacrylamide gel and then transferred to nitrocellulose membrane. The membranes were then blotted with polyclonal antibodies speci®c for the GABP a, and b 2 subunits or a monoclonal antibody against human GABPg. Blots were developed using enhanced chemiluminescence (NEN-Renaissance) and autoradiographed.
DNA constructs
The L6 proximal promoter region was generated by PCR, using the primers 5'-GGGCTAGCGAATTCTTCCTCTTC-CG and 5'-GGAAGCTTGAGCTCACGCCGCGC. Serial 5' deletion mutants, described in Figure 1 , were also generated by PCR using the L6 construct as a template and the following primers: L6dR 5'-GGGCTAGCGAATTCCTTT-TACGTCATCC-3'; USCAAT, 5'-GGGCTAGCGAATTCG-ACTGGGTGGCCAATC-3'; DSCAAT, 5'-GGGCTAGC-GAATTCCAGAGCCCCG-3'; SP-1, 5'-GGGCTAGCTTC-TGTCCCTCCCAT-3'; FA, 5'-GGGCTAGCACCTTGAT-TTCGTAT-3'; UP, 5'-GGGCTAGCCCTTGGTTTCCGT-GG-3'; PR, 5'-GGGCTAGCGGAATTACAGATAAA-3'.
Site directed mutagenesis of the RIBS site was carried out by PCR using Vent (New England Biolabs, Inc.) according to the manufacturer's instructions, using the primers: AAM: 5'-GGGCTAGCGAATTCTTAATCTTTTGTC-3'; TTM: 5'-GG GC TA GC GAATTCTT CCTCTTTTGTCTCTTTCC-3'; CCM: 5'-GGGCTAGCGAATTCTTCCTCTTCCGTCTCT-TTAATTTTACG-3'; AAM/TTM: 5'-GGGCTAGCGAAT-TCTTAATCTTTTGTC-3'; AAM/TTM/CCM: 5'-GGGCT-AGCGAATTCTTAATCTTTTGTCTCTTTAATTTTACG-3'. In all PCR reactions the 3' primer was as described for the L6 PCR product.
All PCR products were digested with NheI and HindIII before cloning into pGL2-basic Luciferase reporter vector (Promega) cut with NheI and HindIII. For the AAM/CCM the CCM construct was used as template with the AAM primer. All constructs were sequenced prior to use in transfections. The RIBS element (5'-GAATTCTTCCTT-TCCGTCTCTTTC-3') was oligomerized, blunted with Klenow ®ll in and cloned into the SmaI site of the G-free TATALuciferase vector, in both forward and reverse orientations.
GABPa, GABPb1-1, GABPb 2 cDNAs cloned in pSK, were a generous gift from SL McKnight. EcoRI and XbaI were introduced into the GABPa and b 2 cDNA by PCR using the primers 5'-GGGAATTCATGACTAAGAGAGAAG-3', 5'-GGTCTAGATCAAATCTCTTTGTCTGC-3', 5'-GGGAA-TTCATGTCTCTGGTGGACTTGG-3' and 5'-GCTCTA-GAT TAGG ATGA AATAGTT TCTAT GG-3' accordingly. The PCR fragments were then cloned into pBS cut with EcoRI and XbaI. The GABPb 1 cDNA subunit was ampli®ed by PCR and EcoRI and BamHI sites were introduced into the cDNA with the primers 5'-GGGAATTCATGTC-CCTGGTAGATTTGG-3' and 5'-GGGGATCCCTAAAC-GGCTTCTTTGTTGG-3'. The PCR fragment was then cloned into pBS cut with EcoRI and BamHI. Each cDNA in pBS was sequenced and then recloned into the maltose binding protein fusion expression vector pMAL-c 2 (New England BioLabs, Inc.). GABPa was cloned using SalI and EcoRI sites, GABPb 1 was cloned using BamHI and EcoRI sites and GABPb 2 was cloned using XbaI and EcoRI sites. Large scale protein preparations were made as previously described (Armstrong et al., 1997) . The GABPa and GABPb 1 subunits in pBS were recloned into the CMV expression vector pSCT-Gal using EcoRI and SalI sites for GABPa and BamHI and EcoRI sites for GABPb 1 .
